Brind.
  1. Kymera Therapeutics and Sanofi announced a collaboration on the IRAK4 program development, focusing on an oral molecular glue degrader.

Sanofi advances Kymera's degrader candidate.

2 reports, 1 independent Updated Nov 3
No new developments lately
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Sanofi advances Kymera's degrader candidate.

Who's involved

What this event is mainly about
Kymera TherapeuticsSanofi

How it developed

Newest first. Tap a step to see who reported it.
  1. Kymera's drug targets eczema and aims to compete with Dupixent.1 source
  2. Sanofi advanced Kymera's degrader candidate in the IRAK4 program.

Keep exploring

Part of

Kymera Therapeutics and Sanofi announced a collaboration on the IRAK4 program development, focusing on an oral molecular glue degrader. All 2 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped